missing translation for 'onlineSavingsMsg'
Learn More

R&D Systems™ Adavosertib

Catalog No. 758950
Change view
Click to view available options
Quantity:
10 mg
50 mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
758950 50 mg
758910 10 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
Catalog No. 758950 Supplier R&D Systems™ Supplier No. 7589/50

Please call Customer Service at 1-800-234-7437 or send an email to help@thermofisher.com for assistance.

A Tocris product, part of R&D Systems. Potent and selective Wee1 inhibitor

Adavosertib is a potent and selective Wee1 inhibitor (IC50 = 5.2 nM). In a panel of 223 serine/threonine or tyrosine kinases, Adavosertib is highly selective for Wee 1 over all except 8 kinases. In particular Adavosertib shows >100-fold selectivity over human Myt1. Adavosertib blocks CDC2Y15 phosphorylation and Gemcitabine (Cat. No. 3259)-induced DNA damage checkpoint, leading to premature mitotic entry and apoptosis in p53-deficient tumor cell lines. Adavosertib also potentiates the cytotoxic effects of Pemetrexed (Cat. No. 6185), Doxorubicin (Cat. No. 2252), Camptothecin (Cat. No. 1100) and Mitomycin C (Cat. No. 3258) in vitro. Adavosertib synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.

Specifications

Chemical Name or Material 1,2-Dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-3 H-pyrazolo[3,4-d]pyrimidin-3-one
CAS 955365-80-7
Quantity 50 mg
Product Line Tocris
Target Checkpoint Control Kinase Inhibitors
Molecular Formula C27H32N8O2
Purity 98%